Tags : canada

Merck Signs Up to $4.5B Oncology Deal with Seattle Genetics

Shots: Seattle Genetics to receive $600M up front, $1B as equity investment, 5M shares of Seattle Genetics common stock at a price of $200/ share, ~$2.6B as milestones including $850M development milestones and $1.75B as commercial milestones. The companies will equally share costs and profits on the global development of ladiratuzumab vedotin and other LIV-1-targeting […]Read More

Takeda Divests its Select Non-Core Assets in the EU and

Shots: Takeda will receive $562M up front for divesting its non-core prescription pharmaceutical products targeting a variety of therapeutic categories sold predominantly in the EU and Canada The divested portfolio includes Takeda’s CV/ metabolic and anti-inflammatory therapeutic areas along with Calcium. The portfolio generated FY 2019 net sales of ~$260M The divestiture further enables Takeda’s […]Read More

Sandoz Launches the Biosimilars Generation Campaign in Canada

Shots: The Biosimilar Generation Campaign provides needed, fact-based, information for patients and HCPs about biosimilar in Canada. The campaign seeks to increase awareness on the benefits of biosimilars and their safety and efficacy The campaign initiated with the launch of the BiosimilarsGeneration.ca,  which support and educate Canadians and provide policy updates from public drug plans […]Read More

Bausch + Lomb Signs an Exclusive License Agreement with STADA

Shots: STADA and Xbrane to receive up front and milestones upon approval and launch of the Xlucane in the US and will be eligible to get an equal share of profits from sales of the biosimilar. The companies aim to obtain all currently approved indications for Lucentis in the US and Canada Xbrane and STADA […]Read More

Biocon and Mylan Launch Fulphila (biosimilar, pegfilgrastim) in Canada

Shots: The companies have launched Fulphila, a biosimilar referencing Neulasta (pegfilgrastim) and is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs The approval is based on analytical, non/clinical data, which showed that Fulphila is highly similar to Neulasta with […]Read More

­Bora Pharmaceuticals to Acquire GSK’s Facility in Canada

Shots: Bora acquires GSK’s facility located in Mississauga, Ontario (Canada) which produces ~50 products and employs ~400 skilled manufacturing staff. The transaction is expected to be completed in H2’20 As per the transaction, GSK’s staff will join the Bora which will continue to manufacture the existing GSK’s product line for a minimum of five years. […]Read More

Bausch + Lomb Collaborates with TerraCycle to Launch First Contact

Shots: The companies will collaboratively launch Bausch + Lomb Every Contact Counts recycling program in eyecare offices across Canada, allowing people to recycle their disposable contact lenses and blister pack packaging The goal of the initiative is to provide an opportunity to eye care professionals and patients to collect waste with an aim to increase […]Read More

JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars

Shots: JAMP to get exclusive commercialization right for Alvotech’s five biosimilar therapies, having the market value of ~2B annually in Canada The collaboration allows JAMP to expand its generic portfolio, expected to exceed 500 products by 2022 and now has six biosimilars in its pipeline leading to an improvement in patient access to the therapies […]Read More